儿童注意缺陷多动障碍(儿童 ADHD) 症状与病因 妙佑医疗国际
儿童注意缺陷多动障碍(儿童 ADHD) - 症状与病因 - 妙佑医疗国际 WeChat
CloseWeibo 显示参考文献 Attention-deficit/hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders DSM-5. 5th ed. Arlington, Va.: American Psychiatric Association; 2013. https://dsm.psychiatryonline.org. Accessed Jan. 26, 2019. Brown A. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Oct. 9, 2018. AskMayoExpert. Attention-deficit/hyperactivity disorder. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2017. Voight RG, et al., eds. Attention-deficit/hyperactivity disorder. In: American Academy of Pediatrics Developmental and Behavioral Pediatrics. 2nd ed. Itasca, IL: American Academy of Pediatrics; 2018. Attention-deficit/hyperactivity disorder. National Institute of Mental Health. https://www.nimh.nih.gov/health/topics/attention-deficit-hyperactivity-disorder-adhd/index.shtml. Accessed Jan 26, 2019. My child has been diagnosed with ADHD ― Now what? Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/adhd/treatment.html. Accessed Jan. 26, 2019. What is ADHD? American Psychiatric Association. https://www.psychiatry.org/patients-families/adhd/what-is-adhd. Accessed Jan. 26, 2019. ADHD. National Alliance on Mental Illness. https://www.nami.org/Learn-More/Mental-Health-Conditions/ADHD/Overview. Accessed Jan. 26, 2019. Ra CK, et al. Association of digital media use with subsequent symptoms of attention-deficit/hyperactivity disorder among adolescents. JAMA. 2018;320:255. For parents and caregivers. National Resource Center on ADHD. https://chadd.org/for-parents/overview/. Accessed Jan. 28, 2019. Complementary and integrative approaches for ADHD: What the science says. National Center for Complementary and Integrative Health. https://nccih.nih.gov/health/providers/digest/adhd-science. Accessed Jan. 28, 2019. Bikic A, et al. Meta-analysis of organizational skills intervention for children and adolescents with attention-deficit/hyperactivity disorder. Clinical Psychology Review. 2017;52:108. Partain PI, et al. New stimulant formulations for pediatric attention-deficit/hyperactivity disorder: A case-based approach for the primary care provider. Current Opinion in Pediatrics. 2019;31:166. Attention-deficit/hyperactivity disorder: Data and statistics. Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/adhd/data.html. Accessed Jan. 30, 2019. Weydert JA, et al. Integrative medicine in pediatrics. Advances in Pediatrics. 2018;65:19. Catala-Lopez F, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PloSOne. 2017;12:e0180355. Mazhar H, et al. Complementary and alternative medicine use in pediatric attention-deficit hyperactivity disorder (ADHD): Reviewing the safety and efficacy of herbal medicines. Current Developmental Disorders Reports. 2016;3:15. Ahn J, et al. Natural product-derived treatments for attention-deficit/hyperactivity disorder: Safety, efficacy, and therapeutic potential of combination therapy. Neural Plasticity. 2016;2016:1320423. American Academy of Pediatrics. Media and young minds. Pediatrics. 2016;138:e20162591. Voight RG, et al., eds. Complementary health approaches in developmental and behavioral pediatrics. In: American Academy of Pediatrics Developmental and Behavioral Pediatrics. 2nd ed. Itasca, IL: American Academy of Pediatrics; 2018. Moran LV, et al. Psychosis with methylphenidate or amphetamine in patients with ADHD. New England Journal of Medicine. 2019;380:1128. Berger S. Attention deficit hyperactivity disorder medications in children with heart disease. Current Opinion in Pediatrics. 2016;28:607. Storebo OJ, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents ― Assessment of adverse events in non-randomised studies. Cochrane Database of Systematic Reviews. https://www.cochranelibrary.com/. Accessed April 1, 2019. Bhagia J (expert opinion). Mayo Clinic, Rochester, Minn. May 13, 2019. Monarch eTNS System (classification order letter). DEN180041. U.S. Food and Drug Administration. https://www.fda.gov/about-fda/cdrh-transparency/evaluation-automatic-class-iii-designation-de-novo-summaries. Accessed June 5, 2019.